Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions

Gethmann, Jörn; Hüttner, Klim; Heyne, Heloise; Probst, Carolina; Ziller, Mario; Beer, Martin; Mettenleiter, Thomas C.; Conraths, Franz J.

doi:10.1016/j.vaccine.2009.04.072

Cited by 53 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher rectal temperatures, with mildto-moderate swelling, were observed in the vaccine groups than in the control group, but no severe clinical signs were observed for any animal. Previous studies of ruminants also demonstrated increases in rectal temperatures following the first and second vaccinations with an inactivated vaccine (48,56), possibly due to the inclusion of strong adjuvants in the vaccine preparations (56). Therefore, decreasing the quantity of adjuvant may avert the similar local reactions and transient hyperthermia observed in the SubV-immunized animals.…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies indicated that the induction of neutralizing antibodies following BTV vaccination is associated with clinical protection, a crucial component of vaccine efficacy (19,45); therefore, the results suggest that the experimental subunit vaccine may induce a level of protection similar to that observed with the commercial inactivated vaccine. Indeed, the ability of the inactivated vaccine to protect ruminants from disease has been shown through its use in the field (43,(46)(47)(48)(49). In addition, it was demonstrated previously that VP2 is a major inducer of neutralizing antibodies following both BTV infection and vaccination (19,26).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Evaluation of the Immunogenicity of an Experimental Subunit Vaccine That Allows Differentiation between Infected and Vaccinated Animals against Bluetongue Virus Serotype 8 in Cattle

Anderson

Hägglund

Bréard

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 98%

Evaluation of the Immunogenicity of an Experimental Subunit Vaccine That Allows Differentiation between Infected and Vaccinated Animals against Bluetongue Virus Serotype 8 in Cattle

Anderson

Hägglund

Bréard

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

“…Specifically, these vaccines generally affected a robust reduction of viremia so that vector transmission and transplacental transmission were prevented (Moulin et al 2012, Batten et al 2013, van der Sluijs et al 2013. Inactivated BTV-8 vaccines are also very safe (Gethmann et al 2009, Probst et al 2011, Leemans et al 2012) and herd and flock immunization compliance has been high (Probst et al 2011).…”

Section: The Role Of Inactivated Vaccines In Control Of Btv-8 In Europementioning

confidence: 99%

Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective

Scott

James

2015

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

Bluetongue (BT) and epizootic hemorrhagic disease (EHD) are noncontagious, insect-transmitted diseases of domestic and wild ruminants caused by related but distinct viruses. There are significant gaps in our scientific knowledge and available countermeasures to control an outbreak of orbivirus-induced disease, whether BT or EHD. Both BT virus (BTV) and EHD virus (EHDV) cause hemorrhagic fevers in susceptible ruminants; however, BT is principally a disease of domestic livestock whereas EHD is principally a disease of certain species of wild, non-African ungulates, notably white-tailed deer. The live-attenuated (modified live virus [MLV]) vaccines available in the United States for use in small ruminant livestock do provide good protection against clinical disease following infection with the homologous virus serotype. Although there is increasing justification that the use of MLV vaccines should be avoided if possible, these are the only vaccines currently available in the United States. Specifically, MLVs are used in California to protect sheep against infection with BTV serotypes 10, 11, and 17, and a MLV to BTV serotype 10 is licensed for use in sheep throughout the United States. These MLV vaccines may need to continue to be used in the immediate future for protective immunization of sheep and goats against BT. There are currently no licensed vaccines available for EHD in the United States other than autogenous vaccines. If there is a need to rapidly develop a vaccine to meet an emerging crisis associated with either BTV or EHDV infections, development of an inactivated virus vaccine in a conventional adjuvanted formulation will likely be required. With two doses of vaccine (and in some instances just one dose), inactivated vaccines can provide substantial immunity to the epizootic serotype of either BTV or EHDV. This strategy is similar to that used in the 2006-2008 BTV serotype 8 outbreaks in northern Europe that provided vaccine to the field within 2 years of the initial incursion (by 2008). Further research and development are warranted to provide more efficacious and effective vaccines for control of BTV and EHDV infections.

show abstract

“…The use of inactivated vaccines avoid risk associated with the use of live-attenuated vaccines, such as reversion to virulence, reassortment of genes with field strain, teratogenicity and insufficient attenuation leading to clinical disease ). Although the hitherto available inactivated vaccines need to be administered twice (particularly in cattle), are rather expensive to produce and are primarily directed against only one serotype, they proved to be safe and effective (Schwartz-Cornil et al 2008, Savini et al 2009, Gethmann et al 2009). Therefore, the European Food Safety Authority currently recommends using inactivated vaccines to protect animals from bluetongue disease (Enserink 2008), instead of MLV vaccines.…”

Section: Inactivated Vaccinesmentioning

confidence: 99%

Bluetongue vaccines in Europe

Niedbalski

2011

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

The article reviews the history, present status and the future of BT vaccines in Europe. So far, an attenuated (modified live viruses, MLV) and inactivated virus vaccines against BT were developed and used in the field. Moreover, the virus-like particles (VLPs) produced from recombinant baculovirus, and live recombinant vaccinia or canarypox virus-vectored vaccines were tested in the laboratory. The main aims of BT vaccination strategy are: to prevent clinical disease, to reduce the spread of the BTV in the environment and to protect movement of susceptible animals between affected and free zones. Actually, all of the most recent European BT vaccination campaigns have used exclusively inactivated vaccines. The use of inactivated vaccines avoid risk associated with the use of live-attenuated vaccines, such as reversion to virulence, reassortment of genes with field strain, teratogenicity and insufficient attenuation leading to clinical disease. The mass vaccinations of all susceptible animals are the most efficient veterinary method to fight against BT and successful control of disease. The vaccination of livestock has had a major role in reducing BTV circulation and even in eradicating the virus from most areas of Europe.

show abstract

Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions

Cited by 53 publications

References 16 publications

Evaluation of the Immunogenicity of an Experimental Subunit Vaccine That Allows Differentiation between Infected and Vaccinated Animals against Bluetongue Virus Serotype 8 in Cattle

Evaluation of the Immunogenicity of an Experimental Subunit Vaccine That Allows Differentiation between Infected and Vaccinated Animals against Bluetongue Virus Serotype 8 in Cattle

Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective

Bluetongue vaccines in Europe

Contact Info

Product

Resources

About